Safety and Efficacy of Aumolertinib in Patients with advanced NSCLC Harboring Uncommon EGFR Mutations: Cohort 2 Updated

被引：0
|
作者：
Fang, W. F. [1 ]
Bu, Q. [2 ]
Wang, Q. M. [3 ]
Zhao, W. H. [4 ]
Wang, L. P. [5 ]
Dong, X. R. [6 ]
Chen, P. F. [7 ]
Wen, Z. B. [8 ]
Jia, J. [9 ]
Jiang, G. M. [9 ]
Zhang, L. [1 ]
机构：
[1] Sun Yat Sen Univ, Ctr Canc, Guangzhou, Peoples R China
[2] Guangxi Med Univ, Affiliated Hosp 1, Nanning, Guangxi, Peoples R China
[3] Henan Canc Hosp, Zhengzhou, Peoples R China
[4] Guangxi Med Univ, Affiliated Tumor Hosp, Nanning, Peoples R China
[5] Baotou Canc Hosp, Baotou, Peoples R China
[6] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Wuhan, Peoples R China
[7] Zhuji Peoples Hosp, Zhuji, Peoples R China
[8] Peoples Hosp Gaozhou, Gaozhou, Peoples R China
[9] Dongguan Peoples Hosp, Dongguan, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
aumolertinib; high-dose; uncommon EGFR mutations;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.09-07
引用
收藏
页码：S333 / S334
页数：2
相关论文
共 50 条
  • [41] A Phase I Study of Afatinib for Patients Aged 75 or Older with Advanced NSCLC Harboring EGFR Mutations
    Baba, K.
    Hasegawa, Y.
    Tanaka, H.
    Taima, K.
    Tanaka, Y.
    Itoga, M.
    Ishioka, Y.
    Morimoto, T.
    Nakagawa, H.
    Takanashi, S.
    Tasaka, S.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2131 - S2132
  • [42] Afatinib in Patients with EGFR Mutation-Positive (EGFRm plus ) NSCLC Harboring Uncommon Mutations: Overview of Clinical Data
    Arrieta, O.
    De Marchi, P.
    Yamamoto, N.
    Yu, C.
    Ou, S. I.
    Zhou, C.
    Paskevicius, M.
    Maerten, A.
    Wu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : S165 - S165
  • [43] Efficacy and Safety of Icotinib in Advanced Non-Small-Cell Lung Cancer Patients Harboring Uncommon EGFR Mutation: a Retrospective Analysis
    Yuan, Xiaobin
    Wang, Yang
    Yang, Min
    Shen, Zhilin
    Chen, Hui
    He, Xiangbo
    Ma, Yongbin
    Ding, Lieming
    LATIN AMERICAN JOURNAL OF PHARMACY, 2023, 42 (01): : 46 - 53
  • [44] Uncommon EGFR mutations conducted with osimertinib in patients with NSCLC (UNICORN): A phase 2 study
    Okuma, Yusuke
    Kubota, Kaoru
    Shimokawa, Mototsugu
    Hashimoto, Kana
    Kawashima, Yosuke
    Sakamoto, Tomohiro
    Wakui, Hiroshi
    Murakami, Shuji
    Okishio, Kyoichi
    Hayashihara, Kenji
    Ohe, Yuichiro
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [45] Efficacy and safety of dacomitinib in advanced non-small cell lung cancer patients harboring uncommon EGFR mutations: Real-world evidence from China.
    Li, Hong-Shuai
    Yang, Guangjian
    Cai, Yi
    Li, Junling
    Xu, Haiyan
    Zhang, Tao
    Zhou, Liqiang
    Luo, Jiancheng
    Wang, Yuying
    Wang, Jinliang
    Hu, Xingsheng
    Liu, Peng
    Yan, Xiang
    Wang, Yan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [46] The Safety and Efficacy of Aumolertinib in Advanced NSCLC Patients with EGFRm Who were Intolerant to Osimertinib: A Retrospective Clinical Study
    Sun, L.
    Huang, X.
    Zhong, M.
    Huang, J.
    Cai, Y.
    Huang, J.
    Liu, H.
    Qin, H.
    Li, J.
    Zhong, B.
    Zuo, H.
    Zhang, G.
    Yan, J.
    Chen, Z.
    Chen, Y.
    He, L.
    Xiong, Y.
    Xu, M.
    Pan, L.
    Xiong, C.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S640 - S641
  • [47] Prospective Study of Aumolertinib in NSCLC Patients with EGFR Sensitive Mutations Who Are Intolerant to Osimertinib Treatment
    Lu, S.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S468 - S468
  • [48] New data on clinical decisions in NSCLC patients with uncommon EGFR mutations
    Wu, Ting-Hui
    Hsiue, Emily Han-Chung
    Lee, Jih-Hsiang
    Lin, Chia-Chi
    Yang, James Chih-Hsin
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2017, 11 (01) : 51 - 55
  • [49] Comparative Clinical Outcomes for Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutations and Common EGFR Mutations
    Girard, N.
    Bazhenova, L.
    Minchom, A.
    Ou, S.
    Gadgeel, S.
    Trigo, J.
    Viteri, S.
    Li, G.
    Mahadevia, P.
    Londhe, A.
    Backenroth, D.
    Li, T.
    Bauml, J. M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S145 - S146
  • [50] EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China
    Xu, Jianlin
    Jin, Bo
    Chu, Tianqing
    Dong, Xue
    Yang, Haitang
    Zhang, Yanwei
    Wu, Dan
    Lou, Yuqing
    Zhang, Xueyan
    Wang, Huiming
    Han, Baohui
    LUNG CANCER, 2016, 96 : 87 - 92
12345